<a href="https://laohu8.com/S/XAGE">Longevity Health</a> Holdings Announces Merger with THPlasma and Ends 20/20 Biolabs Deal
Longevity Health Holdings Inc. (Nasdaq: XAGE) has announced a definitive merger agreement with True Health Inc., operating under the THPlasma brand, in an all-stock transaction aimed at combining their operations. The merger, unanimously approved by the boards of both companies, is slated to close in the fourth quarter of 2025, subject to customary closing conditions. Post-closing, the combined entity will continue trading on Nasdaq under the symbol "XAGE." As part of the agreement, THPlasma is valued at $59 million, with an additional $20 million earnout based on financial performance, and Longevity stock is valued at $3.00. Leadership roles post-merger will see Mr. Rajiv Shukla serving as Executive Chairman, while Mr. George Chi will take on the roles of Co-Chairman and CEO.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longevity Health Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-095608), on July 14, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。